2016 ASCO Annual Meeting Abstract 8007: Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study
KPd is well tolerated and highly active (≥PR 84%) with encouraging PFS (median 12.9 mo) in less pretreated, mostly LEN-refractory and PI-naive/sensitive RRMM in the era of increased use of extended LEN treatment.
ASCO
In The News
American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting